Patient recruitment in clinical trials is a regulated planning process, not a marketing afterthought. FDA guidance issued in December 2025 recommends that sponsors design eligibility criteria, enrollment practices, and trial designs to increase enrollment of representative populations for studies supporting new drug or biologics applications [1]. NIH institutional guidance similarly requires IRB approval for the protocol, recruitment plan, and recruitment materials before any outreach begins [2]. The practical consequence is that recruitment decisions are embedded in protocol development, site feasibility, and data-access workflows long before the first participant is screened. This guide examines those decision points through primary documentation: what regulators expect, how site-level standard operating procedures handle protected health information, and where decentralized trial elements change the recruitment calculus. It closes with a hypothetical evaluation example that shows how a sponsor might compare recruitment channels without inventing performance data.

Regulatory Framing: Recruitment as a Design Question

The FDA's December 2025 guidance frames recruitment as a question of trial design rather than outreach volume. It recommends approaches that sponsors can take to increase enrollment of a representative population, considering demographic characteristics such as sex, race, ethnicity, age, and location of residency, as well as non-demographic characteristics including organ dysfunction, comorbid conditions, disabilities, weight extremes, and low-prevalence diseases [1]. The stated rationale is that enrolling participants with a wide range of baseline characteristics may create a study population that more accurately reflects the patients likely to take the drug if approved and allow assessment of how those characteristics affect safety and effectiveness [1]. This positions eligibility criteria as a recruitment lever: restrictive criteria may simplify analysis but narrow the pool before any outreach occurs.

The guidance applies specifically to clinical trials intended to support a new drug application or a biologics license application, and it was issued by the Center for Drug Evaluation and Research and the Center for Biologics Evaluation and Research [1]. It does not establish binding requirements; FDA guidance documents represent current agency thinking and recommend rather than mandate approaches unless specific regulatory or statutory requirements are cited [6]. For sponsors, this means the December 2025 document is a planning reference, not a compliance checklist. The distinction matters because recruitment strategies that satisfy one review division's expectations may still require protocol-specific justification before an institutional review board.

The IRB Gate: What Must Be Approved Before Outreach

NIH's Office of Human Subjects Research Protections describes recruitment as the process that introduces potential participants to a study and helps them decide whether they are interested in learning more [2]. Before beginning recruitment, investigators must obtain IRB approval for the protocol, the recruitment plan, and the recruitment materials [2]. The recruitment plan itself must describe who will conduct recruitment, how potential participants will be identified and contacted, where recruitment will occur, and when and how potential participants will be approached [2]. The plan should support the scientific objectives of the study while ensuring that no population is unfairly targeted or excluded [2].

Recruitment materials include anything potential participants may see or hear about the study: flyers, posters, brochures, print and broadcast advertisements, emails, letters, telephone or in-person scripts, videos, public service announcements, presentations, and third-party recruitment platforms [2]. Public websites that provide only basic descriptive information, such as a ClinicalTrials.gov listing, do not require IRB review, but websites or social media that actively recruit participants or include information beyond basic study facts generally require IRB review before use [2]. This creates a practical distinction between passive listings and active outreach that sponsors must track across every channel.

A Hypothetical Channel Evaluation for a Site-Based Device Study

Suppose a sponsor is planning a multicenter study of a monitoring device and must choose between two recruitment channels: a ClinicalTrials.gov listing plus referring-provider outreach, or a social media campaign plus a patient registry. A documentation-based evaluation would first confirm that both channels are described in the protocol and that any active social media content has been submitted for IRB review, since active recruitment materials generally require review before use [2]. The sponsor would then map each channel against the recruitment plan elements NIH requires: who conducts outreach, how participants are identified and contacted, where recruitment occurs, and when approaches happen [2].

For the provider-outreach channel, the sponsor would need to verify that each site's SOP permits the proposed identification method. If the plan involves querying electronic medical records, the site must have an IRB-approved recruitment plan describing PHI access or a HIPAA authorization waiver [7]. For the social media channel, the sponsor would need to distinguish between a passive ClinicalTrials.gov listing, which does not require IRB review, and active recruitment content, which generally does [2]. This comparison does not produce a winner; it produces a set of site-level prerequisites that determine whether each channel is even operational. The sponsor would then set trajectory expectations and review recruitment at participating sites regularly, as the Gates Foundation template recommends [4].

Screening Workflows and Protected Health Information

Site-level standard operating procedures show how recruitment intersects with privacy rules. West Virginia University's Clinical Trials Center of Excellence SOP, effective February 2026, states that protected health information may be used for screening for IRB-approved research only if a HIPAA authorization waiver has been approved, an IRB-approved recruitment plan describes the PHI access, or the potential subject has provided written HIPAA authorization [7]. All screening and recruitment plans must be outlined in detail in the IRB submission materials for review and approval prior to implementation [7]. This means a sponsor cannot simply ask a site to query its electronic medical record for eligible patients; the query itself must be pre-authorized.

The same SOP describes a MyChart recruitment workflow in which a clinical member of the study team with EPIC access reviews a report to identify and follow up with patients who have indicated interest, and updates pre-consent statuses in EPIC [7]. Patients receive recruitment messages because their MyWVUChart preferences indicate they would like to be contacted about research studies, and they can change those preferences under Research Studies and Participation Preference [7]. This is a documented example of an opt-in recruitment channel, distinct from medical record review, and it illustrates why recruitment planning must account for local system capabilities and patient consent preferences rather than assuming uniform data access across sites.

Decentralized Elements and Representative Enrollment

FDA's guidance on decentralized clinical trials describes decentralized elements as trial-related activities that occur remotely at locations convenient for participants, including telehealth visits, in-home visits with remote trial personnel, or visits with local health care providers [6]. The guidance states that DCTs have the potential to expand access to more representative patient populations and improve trial efficiencies, and that enabling remote participation may enhance convenience, reduce caregiver burden, and support research on rare diseases and diseases affecting populations with limited mobility or limited access to traditional trial sites [6]. This may help improve participant engagement, recruitment, enrollment, and retention of a more representative population [6].

The guidance also addresses outreach through local health care institutions such as pharmacies and clinics, noting that this may support recruitment of participants with diverse demographic characteristics in areas with limited or no traditional trial sites [6]. Bringing trial-related activities to participants' homes may reduce travel needs and improve engagement among potential participants who have challenges accessing traditional sites, and the use of local health care providers close to participants' homes may further improve engagement and reduce cultural or linguistic barriers to participation [6]. These statements are recommendations about potential effects, not measured outcomes; the guidance does not provide enrollment-rate data comparing decentralized and traditional designs.

Planning Metrics and the Limits of Available Evidence

CTTI's recruitment recommendations, first published in May 2016 and updated in July 2018, emphasize moving recruitment planning upstream and establishing realistic metrics and milestones [5]. The recommendations advise setting realistic expectations for completing trial enrollment by anticipating key factors that influence site activation, screening, and enrollment trajectories, and mapping out anticipated events even if estimations are rough to identify potential bottlenecks [5]. A recruitment budget should, at minimum, assure necessary time, resources, and funds for trial-specific recruitment strategies and pay specific attention to site activation timelines [5]. These are planning disciplines, not performance benchmarks.

The Gates Foundation's recruitment plan template, completed in May 2024, adds operational detail: use a trajectory graph of recruitment so that deviations from the expected trajectory allow investigators to identify periods of slow recruitment, and have the principal investigator or study manager review recruitment at participating sites regularly [4]. The template also recommends spending adequate time pre-screening and screening potential participants, supporting multicultural populations, and ensuring participant compensation is made in a timely manner [4]. None of these documents provides a universal enrollment-rate target, because recruitment feasibility depends on therapeutic area, site infrastructure, and eligibility criteria that vary by protocol.